Trastuzumab deruxtecan TDXd vs trastuzumab emtansine TDM1 in

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

DESTINYBreast03 is a randomized multicenter openlabel phase III study of trastuzumab deruxtecan TDXd versus trastuzumab emtansine TDM1 in patients with human epidermal growth factor receptor 2 HER2positive metastatic breast cancer mBC previously treated with trastuzumab and a taxane A statistically significant improvement in progressionfree survival PFS versus TDM1 was

DESTINYBreast03 trial some questions remain The Lancet

Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer

The approval of TDXd in this setting was based on the results of DESTINYBreast03 NCT03529110 a multicenter phase 3 trial conducted to investigate the efficacy and safety of TDXd versus TDM1

Trastuzumab deruxtecan versus trastuzumab emtansine in patients with

Destiny 3 Trial

S Verma and SA Hurvitz for the DESTINYBreast03 Trial Investigators Original Article 1144 n engl j med 38612 nejmorg March 24 2022 The new england journal of medicine B

Background DESTINYBreast03 NCT03529110 a randomized multicenter openlabel phase 3 study assessed the efficacy and safety of TDXd vs TDM1 in pts with HER2 mBC treated with 1 prior antiHER2 regimen Median m overall survival OS was not reached in either arm at the prior data cutoff DCO Jul 25 2022 We report updated survival results including efficacy and safety after

DESTINYBreast03 Trial ENHERTU famtrastuzumab deruxtecannxki

As reported in The Lancet by Sara A Hurvitz MD and colleagues updated results of the phase III DESTINYBreast03 trial showed significantly improved overall survival with famtrastuzumab deruxtecannxki TDXd vs adotrastuzumab emtansine TDM1 in patients with HER2positive unresectable or metastatic breast cancer who had received a prior antiHER2based regimen

The aim of DESTINYBreast03 was to compare the efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine Methods This openlabel randomised multicentre phase 3 trial was done in 169 study centres in North America Asia Europe Australia and South America

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2positive

Destiny 3 Trial

The pooled safety population reflects exposure to ENHERTU 54 mgkg intravenously every 3 weeks in 1799 patients in Study DS8201AJ101 NCT02564900 DESTINYBreast01 DESTINYBreast02 DESTINYBreast03 DESTINYBreast04 and other clinical trials Among these patients 65 were exposed for 6 months and 38 were exposed for 1 year

We conducted DESTINYBreast03 a phase 3 multicenter openlabel randomized activecontrolled trial to evaluate the efficacy and safety of trastuzumab deruxtecan as compared with trastuzumab

Updated Results of DESTINYBreast03 TDXd vs TDM1 for Previously

DESTINYBreast03 was an openlabel randomised multicentre phase 3 trial that evaluated the efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2positive unresectable or metastatic breast cancer that had progressed during or after treatment with trastuzumab and a taxane 14 The trial was done at 169

Trastuzumab deruxtecan versus trastuzumab emtansine in HER2positive

Sara A Hurvitz and colleagues reported updated results from DESTINYBreast03 a randomised phase 3 trial comparing trastuzumab deruxtecan to trastuzumab emtansine in patients with HER2positive metastatic breast cancer previously treated with trastuzumab and a taxane1 Previously in DESTINYBreast01 trastuzumab deruxtecan showed efficacy as thirdline HER2based treatment after trastuzumab